CVT-510 (CV Therapeutics)
- PMID: 12054080
CVT-510 (CV Therapeutics)
Abstract
CVT-510, the lead compound from a series of selective adenosine A1 receptor agonists, is being developed by CV Therapeutics for the potential treatment of supraventricular tachycardias and atrial arrhythmias [224364], [299365]. Phase II trialsfor atrial fibrillation commenced in December 1999 [349469], while a phase III trial for paroxysmal supraventricular tachycardia (PSVT) began in June 2001; this multicenter, randomized, double-blind, placebo-controlled trial, was to determine the safety and efficacy of CVT-510 in the conversion of PS VT to normal sinus rhythm [414190]. Analysts at Morgan Stanley predicted in December 2001, that the product would befiled with the FDA in 2004 and be launched onto the US market in 2005, with revenues of US $25 million, rising to US $83 million in 2006 [435233].
Similar articles
-
Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans.J Cardiovasc Pharmacol Ther. 2001 Jul;6(3):237-45. doi: 10.1177/107424840100600304. J Cardiovasc Pharmacol Ther. 2001. PMID: 11584330
-
Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist.J Am Coll Cardiol. 2003 Sep 17;42(6):1098-102. doi: 10.1016/s0735-1097(03)00987-2. J Am Coll Cardiol. 2003. PMID: 13678937 Clinical Trial.
-
CVT-510: a selective A1 adenosine receptor agonist.Cardiovasc Drug Rev. 2003 Winter;21(4):277-92. doi: 10.1111/j.1527-3466.2003.tb00122.x. Cardiovasc Drug Rev. 2003. PMID: 14647532 Review.
-
Tecadenoson: a novel, selective A1 adenosine receptor agonist.Cardiol Rev. 2005 Nov-Dec;13(6):315-21. doi: 10.1097/01.crd.0000181621.84565.9d. Cardiol Rev. 2005. PMID: 16230891
-
Conivaptan (Yamanouchi).Curr Opin Investig Drugs. 2002 Jan;3(1):89-95. Curr Opin Investig Drugs. 2002. PMID: 12054079 Review.